Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
Colorcon
Dow
Express Scripts

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,387,603

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,387,603
Title: 1,5,7-trisubstituted indoline compounds and salts thereof
Abstract:Indoline compounds represented by the formula: ##STR1## wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R.sup.1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.
Inventor(s): Kitazawa; Makio (Nagano, JP), Ban; Masaaki (Nagano, JP), Okazaki; Kosuke (Nagano, JP), Ozawa; Motoyasu (Nagano, JP), Yazaki; Toshikazu (Nagano, JP), Yamagishi; Ryoichi (Nagano, JP)
Assignee: Kissei Pharmaceutical Co., Ltd. (Nagano, JP)
Application Number:08/159,624
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,387,603
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 5,387,603

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,387,603

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan4-356197Dec 02, 1992

International Family Members for US Patent 5,387,603

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2110454   Start Trial
Germany 122010000031   Start Trial
Germany 69319551   Start Trial
European Patent Office 0600675   Start Trial C300454 Netherlands   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
AstraZeneca
Harvard Business School
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.